Study details
Enrolling now
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT IDNCT05985161ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
45
Study length
about 6 years
Ages
1+
Locations
15 sites in CA, DC, GA +6
What this study is about
Researchers are testing whether selinexor, a medication, can be an effective treatment for people with relapsed or refractory Wilms tumors, rhabdoid tumors, MPNSTs, or other solid tumors that make too much XPO1. The trial will last approximately 2 years and aims to enroll about 45 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Selinexor
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
selinexor
Drug routes
oral (Oral Tablet)
Endpoints
Primary: Overall Response Rate
Body systems
Oncology